In conclusion, this study consistently identified serum albumin, procalcitonin, and myoglobin as key factors associated with CVD mortality risk in MHD patients. Both models demonstrated promising predictive performance in our cohort. These findings suggest the potential of such models to inform clinical risk assessment. However, external validation in larger, multi-center studies is necessary before these tools can be considered for direct clinical decision-making.
He et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: